 SAN DIEGO, May 17, 2021 GLOBE NEWSWIRE -- Adamis Pharmaceuticals Corporation NASDAQ: ADMP, a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application NDA was resubmitted to the U.S. Food and Drug Administration FDA for ZIMHITM, a naloxone injection product candidate intended for the treatment of opioid overdose. 